Prostatic Neoplasms: Clinical Trials

286 trials for Prostatic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

286 terminated. 286 Phase 2, 63 Phase 1, 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2286Terminated 286
Phase 163Terminated 63
Phase 37Terminated 7

Follow Prostatic Neoplasms: new trials by email Literature Review of Prostatic Neoplasms trials Research Report on Prostatic Neoplasms

Trials (filtered) newest first · largest first

All 286 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
AB-3028 - Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1 / Phase 2TerminatedArsenal Biosciences, Inc.32026-01-092026-11-16
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
Phase 2TerminatedOHSU Knight Cancer Institute62025-06-242026-04-28
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
Apalutamide, Biopsy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Phase 2TerminatedUniversity of Washington82024-05-232026-10-19
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 2TerminatedMayo Clinic82024-03-052026-07-22
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
VIO-01 - Advanced or Metastatic Solid Tumors, Breast Cancer
Phase 1 / Phase 2TerminatedValerio Therapeutics62024-01-102025-03-17
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
TNG348, Olaparib - Breast Cancer, Ovarian Cancer
Phase 1 / Phase 2TerminatedTango Therapeutics, Inc.72023-12-082024-08-13
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
ONCT-534 - Metastatic Castration-resistant Prostate Cancer
Phase 1 / Phase 2TerminatedOncternal Therapeutics, Inc212023-09-202024-12-11
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck
Phase 1 / Phase 2TerminatedEvopoint Biosciences Inc.122023-09-202026-07-23
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
[18]F-PSMA-1007 - Oncology, Prostate Cancer
Phase 2TerminatedAHS Cancer Control Alberta1762023-09-142025-06-12
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
Olaparib, Vitamin C - Prostate Cancer, Castration-resistant Prostate Cancer
Phase 2TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins42023-06-302025-01-29
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
64Cu-SAR-BBN, 67Cu-SAR-BBN - Prostatic Neoplasms, Castration-Resistant
Phase 1 / Phase 2TerminatedClarity Pharmaceuticals Ltd42023-06-152025-08-29
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer
Phase 2TerminatedMacroGenics1922023-06-132026-02-09
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
HB-302/HB-301 Alternating 2-Vector Therapy - Prostate Cancer Metastatic
Phase 1 / Phase 2TerminatedHookipa Biotech GmbH122023-05-232024-06-12
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
Oxycodone, Acetaminophen, Ketamine - Pain Management, Opioid Use
Phase 2 / Phase 3TerminatedWake Forest University Health Sciences582023-04-182026-06-15
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
MDK-703, Checkpoint Inhibitor, Immune - Advanced or Metastatic Solid Tumors
Phase 1 / Phase 2TerminatedMedikine, Inc.262023-02-082024-05-08
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
ChAdOx1-PCAQ, MVA-PCAQ - Prostate Cancer
Phase 1 / Phase 2TerminatedBarinthus Biotherapeutics222023-01-302025-11-10
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
MRI-guided Intensity-Modulated Radiation Therapy, Antiandrogen Therapy, PSMA PET Scan - Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8
Phase 2TerminatedThomas Jefferson University62022-11-162026-03-03
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
TmPSMA-02 - Metastatic Castration-resistant Prostate Cancer
Phase 1 / Phase 2TerminatedTceleron Therapeutics, Inc.12022-09-062023-08-18
Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer
Docetaxel intermittent - Castration Resistant Prostatic Cancer
Phase 2TerminatedAustralian and New Zealand Urogenital and Prostate Cancer Trials Group62022-07-292024-11-22
Massage for Prostate Cancer-Related Fatigue (mPROSTATE)
Swedish Massage Therapy (SMT), Light Touch (LT) Control, Waitlist Control (WLC) - Prostate Carcinoma
Phase 2TerminatedUniversity of Utah282022-06-172026-07-13

Showing 20 of 286. Sign in to see all of them.

Narrower conditions

Neoplasm Metastasis (25)  ·  Neoplasms (16)  ·  Breast Neoplasms (12)  ·  Ovarian Neoplasms (11)  ·  Lung Neoplasms (8)  ·  Carcinoma, Non-Small-Cell Lung (7)  ·  Pancreatic Neoplasms (7)  ·  Colorectal Neoplasms (6)  ·  Small Cell Lung Carcinoma (6)  ·  Urinary Bladder Neoplasms (6)  ·  Esophageal Neoplasms (5)  ·  Genital Neoplasms, Male (5)  ·  Genital Diseases, Male (4)  ·  Prostatic Neoplasms, Castration-Resistant (4)

Broader conditions

Genital Diseases (286)  ·  Male Urogenital Diseases (286)  ·  Urogenital Diseases (286)  ·  Neoplasms by Site (284)  ·  Prostatic Diseases (283)  ·  Genital Diseases, Male (282)  ·  Urogenital Neoplasms (282)  ·  Genital Neoplasms, Male (281)  ·  Neoplasms (270)  ·  Pathological Conditions, Signs and Symptoms (35)  ·  Pathologic Processes (29)  ·  Neoplastic Processes (26)  ·  Female Urogenital Diseases (22)  ·  Female Urogenital Diseases and Pregnancy Complications (22)  ·  Digestive System Diseases (16)

Interventions

Docetaxel (39)  ·  Prednisone (23)  ·  enzalutamide (14)  ·  Abiraterone Acetate (13)  ·  Leuprolide (12)  ·  Gonadotropin-Releasing Hormone (7)  ·  Ketoconazole (7)  ·  Magnetic Resonance Spectroscopy (7)  ·  Metformin (7)  ·  Radiotherapy (7)  ·  acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (7)  ·  olaparib (7)  ·  Androgen Antagonists (6)  ·  abiraterone (6)  ·  bicalutamide (6)

Sponsors

National Cancer Institute (NCI) (13)  ·  M.D. Anderson Cancer Center (6)  ·  OHSU Knight Cancer Institute (6)  ·  University of Washington (6)  ·  University of Wisconsin, Madison (6)  ·  Duke University (5)  ·  Medical University of South Carolina (5)  ·  Rutgers, The State University of New Jersey (5)  ·  The Methodist Hospital Research Institute (5)  ·  Weill Medical College of Cornell University (5)  ·  Roswell Park Cancer Institute (4)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)  ·  University of California, San Francisco (4)  ·  Brown University (3)  ·  Ferring Pharmaceuticals (3)

Countries

United States (236)  ·  Canada (19)  ·  France (17)  ·  United Kingdom (16)  ·  Germany (10)  ·  Spain (10)  ·  Australia (7)  ·  Belgium (6)  ·  Italy (6)  ·  Switzerland (6)  ·  Netherlands (5)  ·  China (4)  ·  Poland (4)  ·  Austria (3)  ·  Denmark (3)

Top investigators

Robert J Amato, DO (6)  ·  Donald L. Trump, MD (3)  ·  Dr. Sandy Srinivas (3)  ·  Mitchell Steiner, MD (3)  ·  Robert S. DiPaola, MD (3)  ·  Andrew Armstrong, MD, ScM (2)  ·  Arie Belldegrun, MD, FACS (2)  ·  Aurelius G Omlin, MD (2)  ·  Channing Paller, MD (2)  ·  Gregory P. Swanson, MD (2)

Results publications

PMID 32897402, PMID 19364971, PMID 20179235, PMID 20818327, PMID 20884247, PMID 21971890, PMID 22932804, PMID 22939385, PMID 23342303, PMID 23877659, PMID 24423462, PMID 24684534, PMID 25128349, PMID 25936597, PMID 27742908, PMID 29361470, PMID 31037562, PMID 31527168, PMID 33015525, PMID 33084183, PMID 33270906, PMID 33465252, PMID 33632874, PMID 34259565, PMID 34665631, PMID 35058326, PMID 35110415, PMID 35428207, PMID 35640474, PMID 36710203, PMID 36753698, PMID 37682613, PMID 37777738, PMID 38452035, PMID 38753757, PMID 38885312, PMID 39076107, PMID 39420060, PMID 39473059, PMID 39503807, PMID 40632975, PMID 40906325, PMID 41428976, PMID 42820295

NIH funding

P30CA072720 (7), 2017 (4), 2019 (3), P30CA012197 (3), P30CA015704 (3), U01CA062491 (3), 2005 (2), 2016 (2), P30CA016056 (2), P30CA016672 (2), P30CA022453 (2), P30CA036727 (2), P30CA069533 (2), P50CA097186 (2), 2009 (1)